Neuralink marked two years of its Telepathy implant with 21 trial participants now steering cursors and robotic arms by thought, even reporting flashes of anticipatory control from early recipient Noland. The company backed that momentum with a $650 million Series E to fund global expansion, launched its first UK trial, GB-PRIME, with two NHS hospital systems, and hired former FDA official David McMullen to run medical affairs and regulatory strategy. It also open-sourced datarepo, the internal platform it built to wrangle the neural, imaging, and manufacturing data generated by all this activity.